颠覆颠覆者?转型期的“上市进程”

Q3 Pharmacology, Toxicology and Pharmaceutics
Accounting Pub Date : 2021-07-14 DOI:10.2139/ssrn.3892419
A. Damodaran
{"title":"颠覆颠覆者?转型期的“上市进程”","authors":"A. Damodaran","doi":"10.2139/ssrn.3892419","DOIUrl":null,"url":null,"abstract":"For decades, private companies planning to enter public markets have used bankers operating as intermediaries, helping them decide on issue timing and pricing, and in meeting disclosure requirements. That banker-led process has always had inefficiencies, but without clear alternatives, companies had to accept the high costs and the money left on the table on the offering date, as bankers set offering prices well below market prices, and rewarded preferred clients. The IPO process is being disrupted by three major changes. First, companies are waiting longer to go public, and are focusing more on scaling up revenues than on building business models that deliver profits, while private. Second, the investor base for IPOs is shifting, from primarily institutional, to include more retail investors, many of whom are young, and get their investing cues more from social media than from roadshows. Third, there are alternatives emerging to the banker-led process, with a few turning to direct listings and many more, especially in the last two years, using special purpose acquisition companies (SPACs). These alternatives clearly are works in progress, and need improvement, but change is coming. In the final part of the paper, we look at disclosures that companies are required to make when they go public, and argue that they not only suffer from bloat, but are not in sync with changes that have occurred in both the companies going public, and those who trade their shares in the immediate aftermath of going public. We argue for reducing disclosure bulk and an easing of restrictions on companies making projections about the future, since these restrictions actually make it easier for companies to sell pie-in-the-sky stories.","PeriodicalId":7317,"journal":{"name":"Accounting","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Disrupting the Disruptors? The 'Going Public Process' in Transition\",\"authors\":\"A. Damodaran\",\"doi\":\"10.2139/ssrn.3892419\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"For decades, private companies planning to enter public markets have used bankers operating as intermediaries, helping them decide on issue timing and pricing, and in meeting disclosure requirements. That banker-led process has always had inefficiencies, but without clear alternatives, companies had to accept the high costs and the money left on the table on the offering date, as bankers set offering prices well below market prices, and rewarded preferred clients. The IPO process is being disrupted by three major changes. First, companies are waiting longer to go public, and are focusing more on scaling up revenues than on building business models that deliver profits, while private. Second, the investor base for IPOs is shifting, from primarily institutional, to include more retail investors, many of whom are young, and get their investing cues more from social media than from roadshows. Third, there are alternatives emerging to the banker-led process, with a few turning to direct listings and many more, especially in the last two years, using special purpose acquisition companies (SPACs). These alternatives clearly are works in progress, and need improvement, but change is coming. In the final part of the paper, we look at disclosures that companies are required to make when they go public, and argue that they not only suffer from bloat, but are not in sync with changes that have occurred in both the companies going public, and those who trade their shares in the immediate aftermath of going public. We argue for reducing disclosure bulk and an easing of restrictions on companies making projections about the future, since these restrictions actually make it easier for companies to sell pie-in-the-sky stories.\",\"PeriodicalId\":7317,\"journal\":{\"name\":\"Accounting\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-07-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Accounting\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2139/ssrn.3892419\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounting","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2139/ssrn.3892419","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 1

摘要

几十年来,计划进入公开市场的私营公司一直利用银行家作为中介,帮助他们决定发行时间和定价,并满足披露要求。银行家主导的流程一直效率低下,但由于没有明确的替代方案,公司不得不接受高昂的成本和发行日剩下的资金,因为银行家将发行价格设定为远低于市场价格,并奖励首选客户。IPO进程受到三大变化的干扰。首先,公司等待上市的时间更长,而且更专注于扩大收入,而不是建立能够在私有化的情况下实现利润的商业模式。其次,IPO的投资者基础正在从主要的机构投资者转变为包括更多的散户投资者,其中许多是年轻人,他们的投资线索更多地来自社交媒体,而不是路演。第三,银行家主导的过程中出现了一些替代方案,其中一些转向直接上市,还有更多,尤其是在过去两年,使用特殊目的收购公司(SPAC)。这些替代方案显然正在进行中,需要改进,但变革即将到来。在论文的最后一部分,我们研究了公司上市时必须披露的信息,并认为它们不仅受到膨胀的影响,而且与上市公司和上市后立即交易股票的公司所发生的变化不同步。我们主张减少披露量,放松对公司预测未来的限制,因为这些限制实际上让公司更容易推销天上掉馅饼的故事。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Disrupting the Disruptors? The 'Going Public Process' in Transition
For decades, private companies planning to enter public markets have used bankers operating as intermediaries, helping them decide on issue timing and pricing, and in meeting disclosure requirements. That banker-led process has always had inefficiencies, but without clear alternatives, companies had to accept the high costs and the money left on the table on the offering date, as bankers set offering prices well below market prices, and rewarded preferred clients. The IPO process is being disrupted by three major changes. First, companies are waiting longer to go public, and are focusing more on scaling up revenues than on building business models that deliver profits, while private. Second, the investor base for IPOs is shifting, from primarily institutional, to include more retail investors, many of whom are young, and get their investing cues more from social media than from roadshows. Third, there are alternatives emerging to the banker-led process, with a few turning to direct listings and many more, especially in the last two years, using special purpose acquisition companies (SPACs). These alternatives clearly are works in progress, and need improvement, but change is coming. In the final part of the paper, we look at disclosures that companies are required to make when they go public, and argue that they not only suffer from bloat, but are not in sync with changes that have occurred in both the companies going public, and those who trade their shares in the immediate aftermath of going public. We argue for reducing disclosure bulk and an easing of restrictions on companies making projections about the future, since these restrictions actually make it easier for companies to sell pie-in-the-sky stories.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Accounting
Accounting Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
自引率
0.00%
发文量
47
审稿时长
20 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信